Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- ClinicalTrials.gov
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
clinical trialBiotech
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level (NCT07649525)
Source-permitted summary
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | Phase: PHASE3 | Conditions: Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
SourceClinicalTrials.govAI Reading Notes
Core signal
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
- Core signal
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | Phase: PHASE3 | Conditions: Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
- Field context
- Protein and Drug Design
- People and labs
- Not stated in the reviewed source.
- Why it matters
- Clinical trial registry updates are translation signals, not commercialization claims by themselves.
- Limits to check
- ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
Research Workflow
Research Workflow
Recommended next steps for turning this signal into research action.
- Read original source
- Check DOI/OpenAlex
- Open relationship graph
- Review people and labs: Not stated in the reviewed source.
- Open linked event for AISci context
- Prepare journal-club PPT: AISci action coming next
- Plan replication checks: AISci action coming next
Publication facts
- Type
- clinical trialSourceClinicalTrials.gov
- Date
- Jul 15, 2026SourceClinicalTrials.gov
- Venue
- ClinicalTrials.govSourceClinicalTrials.gov
- Open access
- openSourceClinicalTrials.gov
External IDs
Author order
No reviewed author edge is attached to this output.
Organizations
No source-confirmed author affiliation is attached.
Related events
Topics
Relationship evidence
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
University of Leeds
Organization linked by public source evidence.
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Clinical/translation signal: Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Timeline
- clinical trialPersonalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level